CA-NETAPP
7.2.2023 14:02:45 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the upcoming availability of the NetApp AFF C-Series, a new family of capacity flash storage options that deliver lower cost all-flash storage, and NetApp AFF A150, a new entry-level storage system in the AFF A-Series family of all-flash systems.
The new NetApp AFF C-Series delivers flash performance, while remaining cost-effective and efficient for a lower total cost of ownership (TCO) and a smaller storage footprint. This family of capacity flash arrays are also offered with one of the industry’s most comprehensive software suites, ONTAP One, an all-in-one license that includes all available NetApp software. Customers can modernize their data center with the flexibility to choose the right storage (performance flash, capacity flash, or hybrid) for their VMware, database, and file workload requirements, all running on NetApp ONTAP and managed centrally by NetApp BlueXP for a seamless hybrid cloud experience.
NetApp also announced today, NetApp Advance, a new portfolio of storage programs and guarantees to deliver best-in-class customer ownership experience and cost-effectively future proof on-premises environments.* This gives customers the flexibility and choice to safeguard their storage investment – whether the C-Series, AFF A150 or other newly acquired AFF or FAS systems – with the ability to right-size on-premises environments and transition to storage as a service or cloud storage as their business requires. And with NetApp’s 4:1 Storage Efficiency Guarantee,* NetApp ensures that workload efficiency goals are met, or NetApp will rectify this at no cost to the customer.
“NetApp has been a flash storage leader for years, and today’s announcements of the AFF C-Series and A150 builds on that legacy of innovation to bring our customers and partners some of the most affordable and sustainable all flash storage in the market today,” said Sandeep Singh, Senior Vice President, Enterprise Storage at NetApp. “As companies are looking at their bottom line in this economic environment, we want to meet their needs by providing capacity flash at a lower cost to entry in order to better enable their transition from hybrid storage to all-flash while staying in budget.”
The NetApp AFF C-Series, which is comprised of the AFF C250, AFF C400 and AFF C800, offers:
- Guaranteed storage efficiency to improve an organization’s storage footprint and energy costs to reduce TCO while simplifying operations.*
- Seamless scalability on-premises to allow organizations to scale capacity and performance as their data grows.
- Best-in-class data security with ransomware protection to keep important data secure, available and protected.
The new NetApp AFF A150 is ideal for Mid-size businesses, and Remote Office/Branch Office (ROBO) and distributed deployments to better meet the needs of customers who require entry-level, enterprise-class storage, while providing:
- Better performance
- More scalability and expansion options
- High availability with support for MetroCluster IP
These additions to NetApp’s product line-up are ideal for entry-level to high-end workloads (including virtual machines, database, and backup consolidation), are feature-rich with ONTAP data management, and are offered at an attractive price point for customers – creating strong growth opportunities for NetApp partners to reach new markets while qualifying for NetApp Partner Sphere incentives.
“NetApp continues to assert itself as one of the market’s preeminent innovators for hybrid cloud storage,” said Juan Orlandini, Chief Architect and Distinguished Engineer at Insight Enterprises. “As a leading solutions integrator and longtime NetApp partner, we know our joint customers are looking for the industry’s most innovative solutions and services to enable speed, scale and resilience for their business. With these new capacity flash and entry level offerings, we’re opening the door to acquire new customers at scale.”
NetApp Advance is available today. The NetApp AFF C-Series family and NetApp AFF A150 will be available starting in March 2023, and NetApp and Cisco plan to offer these storage options within the industry-leading integrated infrastructure offering, FlexPod, in Q4 FY’23.
*Terms and conditions will apply.
Additional Resources
- AFF C-Series
- AFF A-Series
- Blog: Fresh NetApp Innovation to Revolutionize Your Data Center
- Blog: Future-Proof Your Storage Investments with NetApp Advance
- Blog: If You Can’t Measure Sustainability, You Can’t Manage It
- Press Release: NetApp Advance Offers Organizations Next Level Hybrid Cloud Flexibility and Efficiency
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
